Suppr超能文献

平衡态配体结合分析:验证与解读。

Ligand binding assays at equilibrium: validation and interpretation.

机构信息

Division of Physical Biochemistry, MRC National Institute for Medical Research, Mill Hill, London, UK.

出版信息

Br J Pharmacol. 2010 Nov;161(6):1219-37. doi: 10.1111/j.1476-5381.2009.00604.x.

Abstract

The focus of this review paper is factors affecting data interpretation in ligand binding assays under equilibrium conditions. Protocols for determining K(d) (the equilibrium dissociation constant) and K(dA) (the equilibrium inhibitor constant) for receptor ligands are discussed. The basic theory describing the interaction of a radiotracer and an unlabelled competitor ligand with a receptor is developed. Inappropriate experimental design may result in ligand depletion and non-attainment of equilibrium, distorting the calculation of K(d) and K(dA) . Strategies, both theoretical and practical, will be given to avoid and correct such errors, thus leading to the determination of reliable values for these constants. In determining K(dA) from competition binding studies, two additional concepts are discussed. First, the necessity to measure an adequate specific binding signal from the bound radiotracer ligand limits the range of affinity constants that can be measured: a particular set of assay conditions may lead to an upper limit on the apparent affinity of unlabelled ligands. Second, an extension of the basic assay methodology can indicate whether the interaction between the tracer and a test ligand is mediated by a competitive or an allosteric mechanism. Finally, the review ends with a discussion of two factors that are often overlooked: buffer composition and the temperature at which the assay is conducted, and the impact these can have on affinity measurements and the understanding of drug interactions.

摘要

这篇综述论文的重点是讨论在平衡条件下影响配体结合分析中数据解释的因素。讨论了用于确定受体配体的 K(d)(平衡解离常数)和 K(dA)(平衡抑制剂常数)的方案。阐述了描述放射性示踪剂和未标记竞争配体与受体相互作用的基本理论。不适当的实验设计可能导致配体耗尽和未达到平衡,从而扭曲 K(d)和 K(dA)的计算。将给出理论和实际的策略来避免和纠正这些错误,从而确定这些常数的可靠值。在从竞争结合研究中确定 K(dA)时,讨论了另外两个概念。首先,必须从结合的放射性示踪配体中测量足够的特异性结合信号,这限制了可以测量的亲和力常数的范围:特定的一组测定条件可能导致未标记配体的表观亲和力的上限。其次,基本测定方法的扩展可以表明示踪剂和测试配体之间的相互作用是由竞争性还是变构机制介导的。最后,讨论了两个经常被忽视的因素:缓冲液组成和测定进行的温度,以及这些因素对亲和力测量和药物相互作用的理解的影响。

相似文献

1
Ligand binding assays at equilibrium: validation and interpretation.
Br J Pharmacol. 2010 Nov;161(6):1219-37. doi: 10.1111/j.1476-5381.2009.00604.x.
2
Practical aspects of radioligand binding.
Curr Protoc Pharmacol. 2006 Jul;Chapter 1:Unit1.3. doi: 10.1002/0471141755.ph0103s33.
6
Radioligand Binding Assays for Determining Dissociation Constants of Phytohormone Receptors.
Methods Mol Biol. 2016;1450:23-34. doi: 10.1007/978-1-4939-3759-2_3.
7
GPCR-radioligand binding assays.
Methods Cell Biol. 2016;132:191-215. doi: 10.1016/bs.mcb.2015.11.004. Epub 2016 Feb 10.
9
Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.
Br J Pharmacol. 2010 Nov;161(6):1250-65. doi: 10.1111/j.1476-5381.2010.00863.x.

引用本文的文献

2
How THC works: Explaining ligand affinity for, and partial agonism of, cannabinoid receptor 1.
iScience. 2025 May 21;28(7):112706. doi: 10.1016/j.isci.2025.112706. eCollection 2025 Jul 18.
4
Anti-IgD nanobodies as novel tools for studying human IgD biology.
Sci Rep. 2025 Jul 8;15(1):24455. doi: 10.1038/s41598-025-09118-4.
5
Adiabatic-Bias Molecular Dynamics Simulations Reveal the Impact of Mutations on Muscarinic Antagonist Unbinding Kinetics.
J Chem Inf Model. 2025 Jul 14;65(13):7129-7142. doi: 10.1021/acs.jcim.5c00601. Epub 2025 Jun 16.
10
A Robust Expression and Purification Protocol for the Production of the La Domain of Human LARP6.
ACS Omega. 2025 Mar 19;10(12):12699-12709. doi: 10.1021/acsomega.5c01045. eCollection 2025 Apr 1.

本文引用的文献

1
Membrane depolarization causes a direct activation of G protein-coupled receptors leading to local Ca2+ release in smooth muscle.
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11418-23. doi: 10.1073/pnas.0813307106. Epub 2009 Jun 19.
2
The role of binding kinetics in therapeutically useful drug action.
Curr Opin Drug Discov Devel. 2009 Jan;12(1):31-9.
3
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.
Nat Rev Drug Discov. 2009 Jan;8(1):41-54. doi: 10.1038/nrd2760.
4
Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors.
Mol Pharmacol. 2009 Feb;75(2):331-41. doi: 10.1124/mol.108.050963. Epub 2008 Nov 11.
5
Do enthalpy and entropy distinguish first in class from best in class?
Drug Discov Today. 2008 Oct;13(19-20):869-74. doi: 10.1016/j.drudis.2008.07.005. Epub 2008 Aug 26.
6
Limitations and lessons in the use of X-ray structural information in drug design.
Drug Discov Today. 2008 Oct;13(19-20):831-41. doi: 10.1016/j.drudis.2008.06.006. Epub 2008 Aug 27.
7
Structure of a beta1-adrenergic G-protein-coupled receptor.
Nature. 2008 Jul 24;454(7203):486-91. doi: 10.1038/nature07101. Epub 2008 Jun 25.
8
Scintillation proximity assays in high-throughput screening.
Assay Drug Dev Technol. 2008 Jun;6(3):433-55. doi: 10.1089/adt.2008.135.
9
Guide to Receptors and Channels (GRAC), 3rd edition.
Br J Pharmacol. 2008 Mar;153 Suppl 2(Suppl 2):S1-209. doi: 10.1038/sj.bjp.0707746.
10
The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
J Pharmacol Exp Ther. 2008 Jun;325(3):927-34. doi: 10.1124/jpet.108.136978. Epub 2008 Mar 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验